2019 - Fellow of the American Statistical Association (ASA)
John D. Shaughnessy mainly investigates Multiple myeloma, Internal medicine, Gene expression profiling, Cancer research and Molecular biology. He has researched Multiple myeloma in several fields, including Survival rate, Bone marrow, Immunopathology, Pathology and Cytogenetics. His Internal medicine research includes themes of Surgery and Oncology.
His study in Gene expression profiling is interdisciplinary in nature, drawing from both Bioinformatics, Multivariate analysis, Genome, Comparative genomic hybridization and Regulation of gene expression. He combines subjects such as Wnt signaling pathway, DKK1, Gene expression and Protein stabilization with his study of Cancer research. John D. Shaughnessy has included themes like Positional cloning, Monoclonal gammopathy of undetermined significance and Cerebellar Degeneration, Cerebellum in his Molecular biology study.
His primary areas of investigation include Multiple myeloma, Internal medicine, Cancer research, Gene expression profiling and Oncology. His research integrates issues of Bone marrow and Pathology in his study of Multiple myeloma. He interconnects Gastroenterology and Surgery in the investigation of issues within Internal medicine.
His Cancer research research incorporates elements of Cell culture, Wnt signaling pathway, Osteoclast, Osteoblast and Molecular biology. His research in Gene expression profiling intersects with topics in Computational biology, Disease and Bioinformatics. His Oncology research is multidisciplinary, incorporating elements of Cancer, Clinical trial and Survival analysis.
Multiple myeloma, Internal medicine, Cancer research, Gene expression profiling and Oncology are his primary areas of study. His Multiple myeloma research is within the category of Immunology. His work on Hematology and Bortezomib is typically connected to Context as part of general Internal medicine study, connecting several disciplines of science.
The study incorporates disciplines such as Osteoclast, Bone disease, Stem cell and Autocrine signalling in addition to Cancer research. The concepts of his Gene expression profiling study are interwoven with issues in DNA microarray, Computational biology, Chemotherapy and Fluorescence in situ hybridization. The various areas that John D. Shaughnessy examines in his Oncology study include Monoclonal gammopathy of undetermined significance, Clinical trial, Dexamethasone, Risk stratification and Myeloma protein.
John D. Shaughnessy mainly focuses on Multiple myeloma, Gene expression profiling, Immunology, Internal medicine and Oncology. His studies in Multiple myeloma integrate themes in fields like Cancer, Cancer research, Stromal cell, Pathology and Bioinformatics. His Gene expression profiling research includes elements of Computational biology, Cytokine and Gene isoform.
His work on Immunotherapy as part of general Immunology study is frequently connected to Interleukin-6 receptor, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His biological study spans a wide range of topics, including Pharmacogenomics and Monoclonal. His Oncology research is multidisciplinary, relying on both Monoclonal gammopathy of undetermined significance, Clinical trial, Disease and Bortezomib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
Erming Tian;Fenghuang Zhan;Ronald Walker;Erik Rasmussen.
The New England Journal of Medicine (2003)
The molecular classification of multiple myeloma
Fenghuang Zhan;Yongsheng Huang;Yongsheng Huang;Simona Colla;Simona Colla;James P. Stewart;James P. Stewart.
The Microarray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
Leming Shi;Gregory Campbell;Wendell D. Jones;Fabien Campagne.
Nature Biotechnology (2010)
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
Christina M. Annunziata;R. Eric Davis;Yulia Demchenko;William Bellamy.
Cancer Cell (2007)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
R Fonseca;P L Bergsagel;J Drach;J Shaughnessy.
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy;Fenghuang Zhan;Bart E. Burington;Yongsheng Huang.
Genetics and Cytogenetics of Multiple Myeloma A Workshop Report
Rafael Fonseca;Bart Barlogie;Regis Bataille;Christian Bastard.
Cancer Research (2004)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
Bart Barlogie;Guido Tricot;Elias Anaissie;John Shaughnessy.
The New England Journal of Medicine (2006)
Absence epilepsy in tottering mutant mice is associated with calcium channel defects
Colin F Fletcher;Cathleen M Lutz;T.Norene O'Sullivan;John D Shaughnessy.
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
P. Leif Bergsagel;W. Michael Kuehl;Fenghuang Zhan;Jeffrey Sawyer.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: